# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Guggenheim analyst Michael Schmidt downgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Buy to Neutral.
JMP Securities analyst Reni Benjamin downgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Market Outperform to Market Per...
Barclays analyst Peter Lawson upgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Underweight to Equal-Weight and raises t...
U.S. stocks kicked off the week on a positive note, with all major averages edging higher in anticipation of significant events...